옵션 체인은 다양한 행사가격과 만기일에 대한 MoneyLion의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 MoneyLion에 대한 시장 심리를 평가합니다..

MoneyLion (NYSE:ML) 주식, 옵션 체인

MONEYLION INC

MoneyLion

MoneyLion Inc is a mobile banking and financial membership platform that empowers people to take control of their finances. It is a full-service digital platform to deliver mobile banking, lending, and investment solutions. The company offers a personalized, all-in-one, digital financial platform that provides convenient, low-cost access to banking, borrowing, and investing solutions tailored for its customers, rooted in data, and delivered through its proprietary technology platform.

Equities

Macro Economic Events

Macro Notification

Market Summary

News

Sector ETFs

Politics

Treasuries

Economics

Markets

ETFs

COST

INTC

NFLX

NVDA

TSLA

VERA

미국 주식시장은 경제 모멘텀 둔화가 미국 기업들의 실적 전망에 영향을 미칠 수 있다는 투자자들의 우려로 이번 주에 5주 연속 상승세를 마감했다. 미국 경제는 1분기에 연율 1.3% 성장해 이전 추정치 1.6%보다 하향 조정되었다.

이번 주 시장 동향: 월가 5주 연속 상승 마감, 경제 성장 속도 감소, 트럼프의 유죄 평결 등

Southwest Gas Holdings Inc.

Biotech

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

Mid Cap

Health Care

Small Cap

Tech

$BTC

AVGO

CVNA

MSTR

SLNO

엔비디아(NASDAQ:NVDA)는 지난 1년간 수익률 순위에서 나스닥 100 지수 1위를 차지하며 눈에 띄는 기술 주식이었다.
이 칩 제조업의 거인은 인공지능(AI) 개발을 위한 칩에 대한 급증하는 수요로, 지난 2023년 5월 말 이후 무려 186%나 급등했다.

엔비디아는 1년 전 대비 186% 상승했지만, 다음의 7개 주식은 이보다 두 배 이상의 수익 기록

MoneyLion Inc

MoneyLion Inc. Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share

Mesa Laboratories Inc

Mountain Lake Acquisition Corp. - Class A Ordinary Shares

Mountain Lake Acquisition Corp

Mountain Lake Acquisition Corp. - Right

5G Networks Ltd

MELBOURNE IT LTD UNSP/ADR by 5G NETWORKS LTD.

PRIMARY HYDROGEN CORP by PRIMARY HYDROGEN CORP.

ML CAPITAL GROUP INC by ML Capital Group Inc.

ML Capital Group Inc

MILLICOM INTL CELLLR DEP by Millicom International Cellular S.A.

Millicom International Cellular SA

Melco Resorts & Entertainment Limited - American Depositary Shares

Melco Resorts and Entertainment Ltd

Malachite Innovations Inc

Global X Funds Global X Intermediate-Term Treasury Ladder ETF

Moolec Science SA

Major League Football Inc

MAPLE LEAF FOODS INC by Maple Leaf Foods Inc.

Maple Leaf Foods Inc

Malaga Inc

M3 Metals Corp

MALAGA FINANCIAL CORP by Malaga Financial Corp.

Malaga Financial Corp

MicroAlgo Inc

Mitsubishi Estate Logistics REIT Investment Corp

M LINE HOLDINGS INC by M Line Holdings, Inc.

M Line Holdings Inc

Mueller Industries Inc

MOLINOS AGRO SA CL B 1 V by MOLINOS AGRO S A

MiL.k

MALAKOFF CORPORATION BHD by Malakoff Corporation BHD

Malakoff Corp Bhd

MERCATOR MINERALS LTD by Mercator Minerals Ltd.

Mercator Minerals Ltd

MillerKnoll Inc

MEDLINK INTL INC A by MedLink International, Inc.

Medlink International Inc

MOLECULAR PARTNERS AG ORD by Molecular Partners AG

Molecular Partners AG

MULLEN GROUP LTD ORD by Mullen Group Ltd.

Mullen Group Ltd

Malin Corporation PLC

Gabo Mining Ltd

METALLURGICAL CP UNSP/ADR by Metallurgical Corp China Ltd

Metallurgical Corp of China Ltd

Martin Marietta Materials, Inc. Common Stock

Martin Marietta Materials Inc

MCFARLANE LAKE MINING LTD by McFarlane Lake Mining Limited

McFarlane Lake Mining Ltd

MILLENNIUM PRIME INC by Millennium Prime, Inc.

Millennium Prime Inc

Metallica Minerals Ltd

VanEck ETF Trust VanEck Long Muni ETF

Melon - United States Dollar

MeridianLink Inc

MONTELLO RESOURCES LTD by Montello Resources Ltd.

Montello Resources Ltd

Maui Land & Pineapple Company, Inc. Common Stock

Maui Land & Pineapple Co Inc

Global X MLP ETF

ETRACS Alerian MLP Infrastructure Index ETN Series B due April 2, 2040

Global X Funds Global X MLP & Energy Infrastructure Covered Call ETF

MOLECULAR PHARMACOLGY USA by Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology USA Ltd

MLP SE

Millennial Precious Metals Corp

MILLENNIAL POTASH CORP by MILLENNIAL POTASH CORP.

Millennial Potash Corp

Credit Suisse AG Nassau Branch S&P MLP Index Exchange Traded Nt 12/04/2034

ETRACS Quarterly Pay 1.5X Leveraged Alerian MLP Index ETN

Global X MLP & Energy Infrastructure ETF

Miller Industries Inc

Alaska Energy Metals Corp

Metalert Inc

VK CO LTD S/GDR 144A by VK CO LTD.

VK CO LTD S/GDR by VK CO LTD.

Melrose Industries PLC

MELROSE INDUS PLC by Melrose Industries PLC

Melisron Ltd

Milestone Scientific Inc

Melrose Industries PLC ADR

MILC Platform

MULTICONSULT ASA UNSP/ADR by MULTICONSULT ASA

Multiconsult ASA

MOLTEN METALS CORP NEW by MOLTEN METALS CORP.

Molten Metals Corp

MOLTEN METALS CORP by MOLTEN METALS CORP.

Medirect Latino Inc

MULTIPLAN EMPEN UNSP/ADR by Multiplan Empreendimentos Imobiliarios SA

Multiplan Empreendimentos Imobiliarios SA

MULTI UNITS LXEMBRG SCV by Multi Units Luxembourg Sicav

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

Metals X Ltd

Melexis NV

MALAYAN BKNG BERHAD S/ADR by Malayan Banking Berhad

Malayan Banking Bhd

MULTI-METAL DEV LTD by MULTI-METAL DEV LTD.

Multi-Metal Development Ltd

WESTERN MAGNESIUM CORP by Western Magnesium Corp.

Western Magnesium Corp

MALAYAN BKNG BERHAD ORD by Malayan Banking Berhad

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Dave &amp; Buster&#8217;s Entertainment Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) reported fourth-quarter financial results after the market close on Monday. Here&#8217;s a look at the key highlights <a href="https://www.benzinga.com/pressreleases/25/04/g44673682/dave-busters-reports-fourth-quarter-and-fiscal-year-end-2024-financial-results-repurchases-108-mil">from the quarter</a>.
Q4 Earnings: Dave &amp; Buster's reported fourth-quarter revenue of $534.5 million, missing analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $550.37 million, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The entertainment and dining company reported adjusted earnings of 69 cents per share, missing estimates of 71 cents per share.
Total revenue decreased 10.8% year-over-year as comparable store sales fell 9.4%. The company noted that the fourth quarter of 2024 had one less week than the fourth quarter of 2023. 
Dave &amp; Buster&#8217;s said it generated $108.9 million in operating cash flow during the fourth quarter. The company also repurchased approximately five million shares in fiscal 2024, and had approximately $104 million remaining on its buyback as of Monday.
Dave &amp; Buster&#8217;s ended the&nbsp;quarter with&nbsp;$6.9 million&nbsp;in cash and&nbsp;$503.5&nbsp;million&nbsp;of available liquidity under its&nbsp;$650 million&nbsp;revolving credit facility.
&#8220;While we are disappointed by our results in the&nbsp;fourth quarter, we are very encouraged by the clear opportunities we have identified over the past few months and the most recent trends in the business since taking actions to unwind mistakes and make appropriate changes,&#8221; said Kevin Sheehan, board chair and interim CEO of Dave &amp; Buster&#8217;s.
&#8220;Previous leadership, while well-intentioned, made significant and ill-advised changes to marketing, food and beverage, operations, remodels and games investment that negatively impacted the business,&#8221; said Sheehan. 
&#8220;The current leadership team has been systematically unwinding these mistakes and pursuing a &#8216;back to basics&#8217; strategy while making high-confidence improvements to the key areas of the business entirely in line with our previously communicated strategic plan.&#8221; 
Check This Out: <a href="https://www.benzinga.com/government/regulations/25/04/44670193/wall-street-turmoil-deepens-as-trump-threatens-massive-china-tariffs-bitcoin-wobbles-at-78k-whats-driving-markets-monday">Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What&#8217;s Driving Markets Monday?</a>
Last quarter, Dave &amp; Buster&#8217;s announced a CEO transition. The board is currently working with a global executive search firm to find the company&#8217;s next CEO. The company did not provide an update on its CEO search in the fourth-quarter release.
Dave &amp; Buster&#8217;s said it expects total capital expenditures to be less than $220 million in fiscal-year 2025.
Management will further discuss the quarter on a conference call with investors and analysts at 5 p.m. ET. 
PLAY Price Action:&nbsp;Dave &amp; Buster's Entertainment shares were up 2.66% after hours, trading at $16.62 at the time of publication Monday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/alisina">Artography</a>/Shutterstock.

Earnings

Entertainment

Restaurants

Movers

PLAY

Dave & Buster's Q4 Earnings: Revenue Miss, EPS Miss, Unwinding 'Mistakes' From Previous Leadership, 'Clear Opportunities' Ahead

Earned 247 Self-Mined Bitcoin for a Total of 718 Bitcoin Year-to-Date and Our Customers Earned an Estimated 17 Bitcoin at Our Data Centers in March
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.corescientific.com%2F&amp;esheet=54234995&amp;newsitemid=20250407552909&amp;lan=en-US&amp;anchor=Core+Scientific%2C+Inc.&amp;index=1&amp;md5=e44839ee09e874f152e87b20af82499f">Core Scientific, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) ("Core Scientific" or "the Company"), a leader in digital infrastructure for high-performance computing and bitcoin mining,today released unaudited production and operations updates for March 2025.
Key Metrics Summary (unaudited)
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Metric</td>
<td colspan="1" rowspan="1">March 2025</td>
<td colspan="1" rowspan="1">February 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Self-Mining Bitcoin Earned1</td>
<td colspan="1" rowspan="1">247</td>
<td colspan="1" rowspan="1">215</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hosting Bitcoin Earned by Customers2</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">16</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Self-Mined Bitcoin Earned/Day</td>
<td colspan="1" rowspan="1">8.0</td>
<td colspan="1" rowspan="1">7.7</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Self-Mining Energized Hash rate3</td>
<td colspan="1" rowspan="1">18.1</td>
<td colspan="1" rowspan="1">18.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Hosting Energized Hash rate4</td>
<td colspan="1" rowspan="1">1.0</td>
<td colspan="1" rowspan="1">1.0</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Energized Hash rate</td>
<td colspan="1" rowspan="1">19.1</td>
<td colspan="1" rowspan="1">19.4</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Self-Mining Fleet Efficiency (J/TH)5</td>
<td colspan="1" rowspan="1">24.3</td>
<td colspan="1" rowspan="1">24.4</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">1</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Self-Mining Bitcoin Earned represents bitcoin rewards earned by bitcoin miners owned and operated by Core Scientific</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Hosting Bitcoin Earned represents estimated bitcoin rewards earned by customer-owned miners installed and operated by Core Scientific in our data centers, including bitcoin rewards earned by customers and paid to the Company pursuant to proceeds sharing agreements</td>
</tr>
<tr>
<td colspan="1" rowspan="1">3</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Self-Mining Energized Hash Rate represents the total rated capacity of all Company-owned bitcoin miners installed and operating in Core Scientific's data centers. Includes previous generation miners removed to accommodate new miners and then re-deployed opportunistically to exploit favorable mining economics</td>
</tr>
<tr>
<td colspan="1" rowspan="1">4</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Hosting Energized Hash Rate represents the total rated capacity of all hosted bitcoin miners owned by customers, installed and operated by Core Scientific in our data centers</td>
</tr>
<tr>
<td colspan="1" rowspan="1">5</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Average Self-Mining Fleet Efficiency (J/TH) represents the weighted average power consumption in Joules per terahash based on the actual efficiency of each model of miner operating in Core Scientific's owned self-mining fleet</td>
</tr>
</tbody>
</table>
</figure>

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Releases March 2025 Production And Operations Updates Including 247 Self Mined Bitcoins For A Total Of 718 Year-To-Date

On April&nbsp;7, 2025, Federated Hermes Limited, a London, United Kingdom (U.K.)-based subsidiary of Federated Hermes, Inc., entered into a share purchase agreement with Rivington Energy (Management) Limited (Rivington) and its shareholders regarding the acquisition of a majority (60%) equity interest in Rivington. Rivington is a U.K.-based renewable energy project development business. The acquisition was simultaneously completed on April&nbsp;7, 2025.
 &nbsp;
The share purchase agreement provided for an upfront cash payment of £23.7 million ($30.6 million) for the majority (60%) equity interest in Rivington, including stamp duty taxes. The upfront cash payment included a £12.9 million ($16.7 million) capital contribution principally to provide Rivington funds for growth capital and debt repayment. The share purchase agreement also provides for a series of contingent purchase price payments, which can total as much as £10.7 million ($13.8 million) in the aggregate and can become payable annually over the next four years based on certain levels of revenue growth. Rivington had revenues of approximately £7.4 million ($9.5 million) in 2024. The share purchase agreement and other related transaction documents contain certain negotiated warranties, covenants, indemnities, and other terms customary for similar transactions in the U.K.

Federated Hermes Acquires 60% Majority Stake In U.K.-Based Renewable Energy Firm Rivington Energy for £23.7 Million, With Potential Contingent Payments Of Up To £10.7 Million Based On Revenue Growth

Legal

PCRX

Pacira BioSciences Settles Litigations With Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., And eVenus Pharmaceuticals Laboratories Related To Patents For EXPAREL

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 51.37% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 44.01% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 34.83% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 30.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 15.61% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 14.84% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed up 14.17% at $4.75</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 10.08% at $0.43</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 8.89% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 4.89% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 21.51% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 17.47% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 16.17% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 13.73% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 13.32% at $0.12</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 9.51% at $1.43</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 6.88% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 5.58% at $0.39</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 5.49% at $0.56</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 5.17% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 5.17% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 5.11% at $4.05</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.39% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 4.36% at $8.22</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 4.23% at $0.74</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed down 3.22% at $0.92</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

CARA

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNTMF

CPHRF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CXXIF

ELLXF

FFNTF

FUAPF

GBHPF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LMLLF

LVRLF

MRMD

OILFF

RMHB

RSSFF

SOLCF

UGRO

ZDPY

Marijuana Stock Movers For April 7, 2025

Insider Trades

GameStop Form4 Filing Shows CEO Ryan Cohen Bought 500,000 Shares At An Average Price Of $21.55/Share

Billionaire Mark Cuban has never shied away from speaking out about what's wrong with the <a href="https://www.benzinga.com/personal-finance/25/02/43420762/us-health-care-ranks-last-among-wealthy-nations-study-reveals-despite-highest-spending-people-have-lower-than-average-life-expectancies">U.S. healthcare system</a>. In a recent post <a href="https://x.com/mcuban/status/1906368260406145196">on X</a>, Cuban explained that healthcare should be simple, but it's become overly complicated by big insurance companies and pharmacy benefit managers. These groups, he says, act as middlemen, controlling not just the costs but also the accessibility of care.
For Cuban, healthcare should come down to two basic questions:
<ul>
<li>What's the cost?</li>
<li>How can the patient afford it?</li>
</ul>
But according to him, PBMs and <a href="https://www.benzinga.com/25/02/43932776/mark-cuban-slams-fd-up-healthcare-system-blames-insurance-designed-deductibles-for-patient-bankruptcy">insurance companies</a> add unnecessary complexity, controlling which doctors and medications patients can access. Cuban doesn't mince words when it comes to his frustration with this system, saying, "They are able to do so because they control the flow of patients for hospitals/providers and drug manufacturers. They are the gatekeepers for trillions of dollars of healthcare spending. Everyone has to kiss their a&#8211; and accept the complications."
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
<h2 class="wp-block-heading">How PBMs Are Driving Up Drug Prices</h2>
Cuban has been particularly vocal about PBMs, which act as go-betweens for drug manufacturers, pharmacies, and insurers. In a <a href="https://www.drugchannels.net/2024/03/mark-cuban-five-ways-that-big-pbms-hurt.html">post</a> for Drug Channels, he laid out five key ways PBMs are making the healthcare system worse:
<ol>
<li>Lack of Transparency: PBMs often keep their pricing and contracts hidden, making it hard for consumers to shop around and compare prices.</li>
<li>Inflated Specialty Drug Prices: PBMs label certain medications as "specialty drugs" and then drastically increase the prices. However, Cuban wrote that there's "nothing special about most of these drugs."</li>
<li>Rebate Distortion: PBMs negotiate rebates with drug manufacturers, but the savings don't necessarily reach the consumer. Instead, they can lead to higher costs for patients in need of expensive medications.</li>
<li>Formulary Restrictions: PBMs decide which drugs are covered based on their own financial incentives rather than medical necessity, limiting treatment options for patients.</li>
<li>"Sh&#8211;ing on" Independent Pharmacies: "S———ing is the appropriate word to describe the financial abuse that we've heard about from non-captive pharmacies," Cuban wrote." Small, independent pharmacies often can't compete with PBMs, which charge them unpredictable fees and can conduct audits at will, sometimes driving them out of business.</li>
</ol>
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Cuban's Solution: Transparency and Direct-to-Consumer Pricing</h2>
To address these issues, Cuban co-founded <a href="https://www.benzinga.com/personal-finance/25/02/43435413/mark-cubans-cost-plus-marketplace-now-sells-over-6000-medicines-saving-customers-between-40-60-by-cutting-out-the-middle-man">Cost Plus Drug Company</a>. The company cuts out PBMs entirely, offering consumers a chance to buy medications at a transparent price. Cost Plus Drugs charges a fixed 15% markup on the wholesale price, along with a small pharmacy and shipping fee.
In a <a href="https://ldi.upenn.edu/our-work/research-updates/mark-cuban-explains-his-battle-against-pharmacy-benefit-managers/">conversation</a> at the University of Pennsylvania, Cuban pointed out how much trust has been lost in the healthcare system. He says that transparency could be the key to winning that trust back. That's why his company is committed to showing consumers exactly what they're paying for—something that most drug pricing models don't do.
See Also: <a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.
<h2 class="wp-block-heading">Can Healthcare Reform Fix the Problem?</h2>
Cuban has repeatedly said that <a href="https://www.benzinga.com/personal-finance/24/12/42742855/mark-cuban-says-this-is-single-payer-how-his-healthcare-model-could-transform-the-u-s-healthcare-system">removing PBMs from the equation</a> would make healthcare more affordable and clear. He argues that if PBMs were out of the picture, the trillions of dollars saved could go toward helping the patients who can't afford care.
"There is a fix," Cuban wrote. "The federal government, states, and self-insured employers can stop doing business with the big three PBMs…State and federal agencies and big companies could switch out from those big PBMs and use their competitors. This would change an entire industry in less than five years."
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

Personal Finance

Mark Cuban Says Big Insurance Companies And PBMs Control Healthcare Costs, 'Everyone Has To Kiss Their A-- And Accept The Complications'

Despite Wall Street continuing to tumble at the start of the second quarter of 2025, a small group of S&amp;P 500 stocks has remained nearly untouched by the chaos triggered by <a href="https://www.benzinga.com/topic/tariffs">Donald Trump's tariff policies.</a>
Stocks that delivered standout gains in the first quarter have held their ground through the opening week of the second quarter, showing resilience as the broader market sank under pressure from tariffs and softening earnings outlooks.
The five best-performing S&amp;P 500 names in Q1 2025 — CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), Cencora Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) — have seen only minimal declines in recent days, defying a sharp 10% drop in the S&amp;P 500 index fueled by mounting trade tensions and concerns over recession. 
<h3 class="wp-block-heading">Quarterly Stars In A Cloudy Market</h3>
Let's break it down:
<ul>
<li>CVS Health soared 50.9% in Q1, posting its best quarterly gain since 1975. While the S&amp;P 500 dropped 10% in the first week of April, CVS is only down 5% in Q2.</li>
<li>Philip Morris jumped 31.9% last quarter, reaching multiple record highs and logging its second-best quarter since going public in 2008. PM is down 4.8% thus far in April.</li>
<li>Newmont rode the gold wave. With gold prices up 19%, the mining giant surged 29.7%, its strongest 3-month performance since early 2020. NEM fell 7.2% in Q2, yet showed a more contained drop than the broader market.</li>
<li>Cencora, formerly AmerisourceBergen, posted a 23.8% rise, and remains up 0.2% this month, dodging the tariff-driven downturn.</li>
<li>Vertex Pharmaceuticals climbed 21% in Q1, and has stayed flat so far in Q2, showing impressive stability in biotech.</li>
</ul>
<h3 class="wp-block-heading">But How Much More Room To Run?</h3>
Despite their impressive runs, future gains may be limited. Analyst consensus shows only Newmont and CVS have potential upside of 25.8% and 13.2%, respectively, based on median price targets. 
For the others, the path forward looks far less compelling. With valuations already stretched and macroeconomic risks mounting — from renewed trade tensions to signs of weakening corporate margins — the potential for further gains could quickly evaporate if analysts begin slashing forecasts in the coming weeks.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Q1 2025 Price Change</th>
<th>YTD Price Change</th>
<th>Median Target Upside</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health (CVS)</td>
<td>+50.9%</td>
<td>+43.71%</td>
<td>+13.16%</td>
</tr>
<tr>
<td>Philip Morris (PM)</td>
<td>+31.9%</td>
<td>+26.02%</td>
<td>+2.86%</td>
</tr>
<tr>
<td>Newmont Corporation (NEM)</td>
<td>+29.7%</td>
<td>+21.77%</td>
<td>+25.77%</td>
</tr>
<tr>
<td>Cencora Inc. (COR)</td>
<td>+23.8%</td>
<td>+23.78%</td>
<td>+0.68%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals (VRTX)</td>
<td>+21.0%</td>
<td>+19.20%</td>
<td>+6.66%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data as of April 7, 2025</figcaption></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44667104/speculators-raise-wagers-on-fed-emergency-rate-cuts-as-theories-of-self-induced-crash-gather-pace">Emergency Fed Rate Cut Odds Spike As Trump Says &#8216;No Inflation,&#8217; Calls for Immediate Action</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Comments

MoneyLion

MoneyLion (ML) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌